A Response to the Letter to the Editor: "Lazertinib Versus Osimertinib in EGFR-Mutant NSCLC: Efficacy, Toxicity, and Unaddressed Clinical Gaps".
Journal
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Journal Volume
21
Journal Issue
1
Start Page
199
End Page
200
ISSN
1556-1380
Date Issued
2026-01
Author(s)
Type
letter